Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myeloma bone disease.

Orhan Sezer1

  • 1Department of Hematology and Oncology, University Hospital Charité, Berlin, Germany.

Hematology (Amsterdam, Netherlands)
|September 29, 2005
PubMed
Summary
This summary is machine-generated.

Multiple myeloma causes bone destruction by increasing osteoclast activity and decreasing osteoblast function. Inhibiting bone resorption may treat both bone disease and tumor progression in multiple myeloma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.

British journal of haematology·2021
Same author

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.

The Lancet. Oncology·2021
Same author

Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis.

Leukemia·2019
Same author

Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.

British journal of haematology·2017
Same author

Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.

Haematologica·2016
Same author

European Myeloma Network guidelines for the management of multiple myeloma-related complications.

Haematologica·2015
Same journal

Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene and regulating C-MYC expression.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Characterization of a novel α-thalassemia deletion (Dongxing deletion; --<sup>DX</sup>) by CNV-seq in a Chinese female with Hb H disease: a case report.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Sirolimus-based treatment regimens for antinuclear antibody (ANA)-positive immune thrombocytopenia: a retrospective single-center cohort study.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Relationship between major depressive disorder and venous thromboembolism: a five-ancestry genetic analysis.

Hematology (Amsterdam, Netherlands)·2026
See all related articles

Area of Science:

  • Oncology
  • Bone Metabolism
  • Immunology

Background:

  • Multiple myeloma is characterized by significant bone destruction.
  • Tumor progression in multiple myeloma is closely linked to bone resorption.
  • Myeloma cells disrupt bone metabolism by activating osteoclasts and inhibiting osteoblasts.

Purpose of the Study:

  • To investigate the mechanisms of bone destruction in multiple myeloma.
  • To explore the relationship between bone resorption and tumor progression.
  • To evaluate therapeutic strategies targeting bone resorption.

Main Methods:

  • Analysis of the bone marrow microenvironment in multiple myeloma.
  • Assessment of osteoclast and osteoblast activity.
  • Evaluation of myeloma cell-secreted factors (RANKL, OPG, MIP-1alpha, MIP-1beta, DKK-1).

Related Experiment Videos

Main Results:

  • Myeloma cells increase receptor activator of NF-kappaB ligand (RANKL) and decrease osteoprotegerin (OPG) expression, promoting osteoclastogenesis.
  • Myeloma cells secrete chemokines (MIP-1alpha, MIP-1beta, SDF-1alpha) that enhance osteoclast activity.
  • Myeloma cells produce Dickkopf (DKK)-1, inhibiting osteoblast function.
  • Bone destruction releases cytokines that stimulate myeloma cell growth, creating a vicious cycle.

Conclusions:

  • Inhibiting bone resorption offers a potential therapeutic strategy for multiple myeloma.
  • Targeting osteoclast activity (e.g., via bisphosphonates, RANKL blockade, or chemokine inhibition) can reduce both bone disease and tumor growth.
  • Understanding the interplay between myeloma and bone metabolism is crucial for developing effective treatments.